Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;62(2):477-486.
doi: 10.1007/s12020-018-1682-5. Epub 2018 Jul 19.

Androgenic modulation of AR-Vs

Ana Caroline Hillebrand  1 , Lolita Schneider Pizzolato  1 , Gisele Branchini  2 , Ilma Simoni Brum  3   4
Affiliations

Androgenic modulation of AR-Vs

Ana Caroline Hillebrand et al. Endocrine. 2018 Nov.

Abstract

Purpose: The importance of androgen receptor variants (AR-Vs) is recognized in prostate cancer. AR-Vs have been the focus of many studies. Expression of AR-Vs has been proposed as a biomarker for resistance to androgen deprivation therapy for metastatic disease. Herein, we show dynamic changes in AR-Vs expression in response to androgen modulation.

Methods: The C4-2B cell line was exposed to low (10-13 M) and high (10-8 M) androgen (dihydrotestosterone, DHT) levels, with or without flutamide. mRNA and protein expression levels were assessed by qPCR and immunohistochemistry, respectively.

Results: We demonstrated that high levels of DHT downregulate AR-FL and AR-Vs. Even though AR-Vs did not present ligand-binding domain, thus were not capable of binding to DHT, they present dynamic changes under androgen treatment. Treatment with flutamide alone or in association with low levels of DHT stimulates growth of prostatic cells.

Conclusions: Importantly, we provide evidence that AR-Vs respond differently to androgenic modulation. These findings have implications for a better understanding of the role of AR-Vs in prostate carcinogenesis.

Keywords: Androgen receptor; Androgen receptor isoforms; Androgen receptor variants; Androgenic modulation; Prostate cancer; Steroids.

PubMed Disclaimer

References

    1. Nat Med. 2004 Jan;10(1):33-9 - PubMed
    1. J Biol Chem. 2012 Jun 1;287(23):19736-49 - PubMed
    1. Clin Cancer Res. 2005 Jul 1;11(13):4653-7 - PubMed
    1. Eur Urol. 2018 May;73(5):727-735 - PubMed
    1. Cancer Res. 2002 Mar 1;62(5):1496-502 - PubMed

LinkOut - more resources